Kalypsys has multiple, structurally diverse, preclinical stage candidates which are positioned as development backups to KD7040.
Nitric oxide (NO) generation via the inducible nitric oxide synthase (iNOS) pathway has been implicated in the pathophysiology of a variety of inflammatory disease states. Kalypsys is developing an inducible nitric oxide synthase (iNOS) dimerization inhibitor as an oral agent for the treatment of neuropathic pain, inflammatory pain, and asthma. Current preclinical stage leads demonstrate low nanomolar potency against the human iNOS isoform, selectivity over eNOS and nNOS, and efficacy in vivo.
P38 MAP kinase inhibition is a clinically important target for chronic inflammatory conditions such as arthritis. Kalypsys has identified novel, preclinical stage, highly selective chemical leads that demonstrate reversal of ongoing inflammation in an established adjuvant arthritis model in the rat.